vedolizumab
takeda
['vedolizumab', ' vedo', 'earnest trial', 'ulcerative colitis', 'ibd', ' uc ']
 key points on vesolizumab. 1. best positioned for 1st line therapy 2. effective for chronic pouchitis 3. sq version is coming 4. may be preferred agent for checkpoint inhibitor colitis. #aibd2022 
IBD doctor @OHSU | Life and Health Coach | Tweets are my own and are not medical advice